Akoya Biosciences, Inc.’s AKYA share price has dipped by 7.20%, which has investors questioning if this is right time to buy.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.65 from $2.40 and keeps a Neutral ...

Piper Sandler analyst David Westenberg maintained a Hold rating on Akoya Biosciences (AKYA – Research Report) today and set a price target of ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today announced that it has filed ...

Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challengesinitiative The unprecedented scale ...

SAMBAI, a team funded through the Cancer Grand Challenges initiative, reported that Akoya Biosciences’ PhenoCycler ®-Fusion system will be the foundational spatial proteomics technology used to ...

The real shocker was that the company announced the purchase of Akoya Biosciences (AKYA) in order to integrate spatial biology capabilities in tissue with ultra-sensitive detection of biomarkers ...

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences ...